Michael Merchlinsky

2.3k total citations · 1 hit paper
44 papers, 1.9k citations indexed

About

Michael Merchlinsky is a scholar working on Virology, Molecular Biology and Epidemiology. According to data from OpenAlex, Michael Merchlinsky has authored 44 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Virology, 21 papers in Molecular Biology and 17 papers in Epidemiology. Recurrent topics in Michael Merchlinsky's work include Poxvirus research and outbreaks (29 papers), Bacillus and Francisella bacterial research (17 papers) and Virus-based gene therapy research (15 papers). Michael Merchlinsky is often cited by papers focused on Poxvirus research and outbreaks (29 papers), Bacillus and Francisella bacterial research (17 papers) and Virus-based gene therapy research (15 papers). Michael Merchlinsky collaborates with scholars based in United States, Canada and Russia. Michael Merchlinsky's co-authors include Bernard Moss, David C. Ward, Clement A. Meseda, Brett W. Petersen, Jerry P. Weir, Caroline R. Astell, Agam K. Rao, Jafar H. Razeq, Doug Campos‐Outcalt and Sol Roy Rosenthal and has published in prestigious journals such as Cell, Nucleic Acids Research and PLoS ONE.

In The Last Decade

Michael Merchlinsky

44 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

2022 295 citations Agam K. Rao, Brett W. Petersen et al. MMWR Morbidity and Mortality Weekly Report profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Merchlinsky United States	24	1.2k	820	774	628	388	44	1.9k
Susan L. Ropp United States	14	877 0.7×	701 0.9×	714 0.9×	382 0.6×	426 1.1×	17	1.5k
Tilahun Yilma United States	26	1.0k 0.9×	952 1.2×	416 0.5×	498 0.8×	589 1.5×	83	2.2k
Igor V. Babkin Russia	20	874 0.7×	687 0.8×	751 1.0×	261 0.4×	362 0.9×	78	1.5k
Rafael Nájera Spain	21	1.4k 1.2×	543 0.7×	332 0.4×	155 0.2×	1.2k 3.2×	40	2.0k
Scott Parker United States	24	1.3k 1.1×	1.0k 1.2×	931 1.2×	248 0.4×	287 0.7×	42	1.7k
Michael P. Dempsey United States	13	1.9k 1.6×	484 0.6×	1.1k 1.4×	707 1.1×	1.2k 3.0×	23	2.8k
E A Duarte United States	13	241 0.2×	229 0.3×	370 0.5×	868 1.4×	400 1.0×	15	1.5k
Lilly Yuen Australia	28	417 0.4×	1.7k 2.1×	260 0.3×	242 0.4×	685 1.8×	71	2.4k
H. Meyer Germany	18	866 0.7×	684 0.8×	452 0.6×	373 0.6×	170 0.4×	45	1.2k
R.B. Naso United States	16	382 0.3×	221 0.3×	495 0.6×	423 0.7×	315 0.8×	27	1.2k

Countries citing papers authored by Michael Merchlinsky

Since Specialization

Citations

This map shows the geographic impact of Michael Merchlinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Merchlinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Merchlinsky more than expected).

Fields of papers citing papers by Michael Merchlinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Merchlinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Merchlinsky. The network helps show where Michael Merchlinsky may publish in the future.

Co-authorship network of co-authors of Michael Merchlinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Merchlinsky. A scholar is included among the top collaborators of Michael Merchlinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Merchlinsky. Michael Merchlinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carbonnelle, Caroline, Delphine Pannetier, Stéphane Mély, et al.. (2022). Natural History of Sudan ebolavirus to Support Medical Countermeasure Development. Vaccines. 10(6). 963–963. 11 indexed citations

Rao, Agam K., Brett W. Petersen, Florence Whitehill, et al.. (2022). Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morbidity and Mortality Weekly Report. 71(22). 734–742. 295 indexed citations breakdown →

Wolfe, Daniel, Carol L. Sabourin, Michael Merchlinsky, et al.. (2021). Selection of Filovirus Isolates for Vaccine Development Programs. Vaccines. 9(9). 1045–1045. 5 indexed citations

Merchlinsky, Michael, et al.. (2019). The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Research. 168. 168–174. 70 indexed citations

Warren, Robin M., et al.. (2018). Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule. Frontiers in Cellular and Infection Microbiology. 8. 356–356. 7 indexed citations

Meseda, Clement A., et al.. (2013). Effect of the Deletion of Genes Encoding Proteins of the Extracellular Virion Form of Vaccinia Virus on Vaccine Immunogenicity and Protective Effectiveness in the Mouse Model. PLoS ONE. 8(6). e67984–e67984. 10 indexed citations

He, Yong, Jody Manischewitz, Clement A. Meseda, et al.. (2007). Antibodies to the A27 Protein of Vaccinia Virus Neutralize and Protect against Infection but Represent a Minor Component of Dryvax Vaccine–Induced Immunity. The Journal of Infectious Diseases. 196(7). 1026–1032. 27 indexed citations

Laassri, Majid, et al.. (2007). Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene. Journal of Medical Virology. 79(6). 791–802. 9 indexed citations

Puig, Montserrat, Kathleen Mihalik, John C. Tilton, et al.. (2006). CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology. 44(3). 736–745. 64 indexed citations

10.

García, Alonzo D., Clement A. Meseda, Yong He, et al.. (2005). Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology. 343(1). 128–140. 40 indexed citations

11.

Merchlinsky, Michael, et al.. (2005). Identification of a novel immunodominant cytotoxic T lymphocyte epitope derived from human factor VIII in a murine model of hemophilia A. Thrombosis Research. 116(4). 335–344. 3 indexed citations

12.

Manischewitz, Jody, Lisa R. King, Joseph Shiloach, et al.. (2003). Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene Expression. The Journal of Infectious Diseases. 188(3). 440–448. 53 indexed citations

13.

Li, Zhongqi, Steven A. Rubin, Rolf E. Taffs, et al.. (2003). Mouse neurotoxicity test for vaccinia-based smallpox vaccines. Vaccine. 22(11-12). 1486–1493. 22 indexed citations

14.

Meseda, Clement A., Karen L. Elkins, Michael Merchlinsky, & Jerry P. Weir. (2002). Prime‐Boost Immunization with DNA and Modified Vaccinia Virus Ankara Vectors Expressing Herpes Simplex Virus–2 Glycoprotein D Elicits Greater Specific Antibody and Cytokine Responses than DNA Vaccine Alone. The Journal of Infectious Diseases. 186(8). 1065–1073. 48 indexed citations

15.

Rosenthal, Sol Roy, et al.. (2001). Developing New Smallpox Vaccines. Emerging infectious diseases. 7(6). 920–926. 108 indexed citations

16.

Wyatt, Linda S., Miles W. Carroll, Claus‐Peter Czerny, et al.. (1998). Marker Rescue of the Host Range Restriction Defects of Modified Vaccinia Virus Ankara. Virology. 251(2). 334–342. 68 indexed citations

17.

Merchlinsky, Michael, et al.. (1997). Construction and Characterization of Vaccinia Direct Ligation Vectors. Virology. 238(2). 444–451. 21 indexed citations

18.

Merchlinsky, Michael & Bernard Moss. (1992). Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: Recombination-independent selectable cloning vectors. Virology. 190(1). 522–526. 60 indexed citations

19.

Merchlinsky, Michael, Claude F. Garon, & Bernard Moss. (1988). Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Journal of Molecular Biology. 199(3). 399–413. 45 indexed citations

20.

Merchlinsky, Michael & Bernard Moss. (1988). Sequence independent replication and sequence specific resolution of plasmids containing the vaccinia virus concatemer junction requirements for early and late trans acting factors. 87–94. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact